<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: Allergy Therapeutics secures financing	</title>
	<atom:link href="https://ukinvestormagazine.co.uk/allergy-therapeutics-secures-financing/feed/" rel="self" type="application/rss+xml" />
	<link>https://ukinvestormagazine.co.uk/allergy-therapeutics-secures-financing/</link>
	<description>UK Investor Magazine provides breaking financial news and investment ideas</description>
	<lastBuildDate>Mon, 19 Jun 2023 11:11:15 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>
	<item>
		<title>
		By: Allergy Therapeutics drops 72% on results and suspension lifting &#8211; Invest Money UK		</title>
		<link>https://ukinvestormagazine.co.uk/allergy-therapeutics-secures-financing/#comment-23080</link>

		<dc:creator><![CDATA[Allergy Therapeutics drops 72% on results and suspension lifting &#8211; Invest Money UK]]></dc:creator>
		<pubDate>Mon, 19 Jun 2023 11:11:15 +0000</pubDate>
		<guid isPermaLink="false">https://ukinvestormagazine.co.uk/?p=64071#comment-23080</guid>

					<description><![CDATA[[&#8230;] that capital problem: “On 6 April 2023, the Group entered into a senior secured facility agreement in an aggregate principal amount of £40.75m to refinance the existing £10 million loan notes issued on 28 February 2023, to continue key [&#8230;]]]></description>
			<content:encoded><![CDATA[<p>[&#8230;] that capital problem: “On 6 April 2023, the Group entered into a senior secured facility agreement in an aggregate principal amount of £40.75m to refinance the existing £10 million loan notes issued on 28 February 2023, to continue key [&#8230;]</p>
]]></content:encoded>
		
			</item>
	</channel>
</rss>
